Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy

E Zonari, G Desantis, Carolina Petrillo, FE Boccalatte, MR Lidonnici, A Kajaste-Rudnitski, A Aiuti, G Ferrari, L Naldini, B Gentner

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. © 2017 The Author(s)
Original languageEnglish
Pages (from-to)977-990
Number of pages14
JournalStem Cell Reports
Volume8
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Gene therapy
Hematopoietic Stem Cells
Stem cells
Genetic Therapy
Cells
Population
Blood
Stem Cells
Genetic engineering
Genetic Engineering
Sorting
Cell culture
Dinoprostone
Sustainable development
Blood Cells
Genes
Transplantation
Clinical Trials
Derivatives
Safety

Cite this

Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy. / Zonari, E; Desantis, G; Petrillo, Carolina; Boccalatte, FE; Lidonnici, MR; Kajaste-Rudnitski, A; Aiuti, A; Ferrari, G; Naldini, L; Gentner, B.

In: Stem Cell Reports, Vol. 8, No. 4, 2017, p. 977-990.

Research output: Contribution to journalArticle

@article{34a514d4f74e42368ad20c51d8a3a8b1,
title = "Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy",
abstract = "Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90{\%} of HSC activity in less than 10{\%} of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. {\circledC} 2017 The Author(s)",
author = "E Zonari and G Desantis and Carolina Petrillo and FE Boccalatte and MR Lidonnici and A Kajaste-Rudnitski and A Aiuti and G Ferrari and L Naldini and B Gentner",
year = "2017",
doi = "10.1016/j.stemcr.2017.02.010",
language = "English",
volume = "8",
pages = "977--990",
journal = "Stem Cell Reports",
issn = "2213-6711",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Efficient Ex Vivo Engineering and Expansion of Highly Purified Human Hematopoietic Stem and Progenitor Cell Populations for Gene Therapy

AU - Zonari, E

AU - Desantis, G

AU - Petrillo, Carolina

AU - Boccalatte, FE

AU - Lidonnici, MR

AU - Kajaste-Rudnitski, A

AU - Aiuti, A

AU - Ferrari, G

AU - Naldini, L

AU - Gentner, B

PY - 2017

Y1 - 2017

N2 - Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. © 2017 The Author(s)

AB - Ex vivo gene therapy based on CD34+ hematopoietic stem cells (HSCs) has shown promising results in clinical trials, but genetic engineering to high levels and in large scale remains challenging. We devised a sorting strategy that captures more than 90% of HSC activity in less than 10% of mobilized peripheral blood (mPB) CD34+ cells, and modeled a transplantation protocol based on highly purified, genetically engineered HSCs co-infused with uncultured progenitor cells. Prostaglandin E2 stimulation allowed near-complete transduction of HSCs with lentiviral vectors during a culture time of less than 38 hr, mitigating the negative impact of standard culture on progenitor cell function. Exploiting the pyrimidoindole derivative UM171, we show that transduced mPB CD34+CD38− cells with repopulating potential could be expanded ex vivo. Implementing these findings in clinical gene therapy protocols will improve the efficacy, safety, and sustainability of gene therapy and generate new opportunities in the field of gene editing. © 2017 The Author(s)

U2 - 10.1016/j.stemcr.2017.02.010

DO - 10.1016/j.stemcr.2017.02.010

M3 - Article

VL - 8

SP - 977

EP - 990

JO - Stem Cell Reports

JF - Stem Cell Reports

SN - 2213-6711

IS - 4

ER -